Akonni Biosystems is a molecular diagnostics company that develops, manufactures, and will market sophisticated genetic testing devices for complex infectious and human health diseases, like Methicillin-resistant Staphylococcus aureus (MRSA), multi-drug-resistant tuberculosis (MDR-TB), and influenza sub-typing with oseltamivir-resistance detection. Our approach is based on an evolutionary gel-drop microarray platform and will include both rapid, low-cost diagnostic tests and transportable test readers for point-of-care testing. We will also market high-throughput screening systems based on our gel-drop microarray technology capable of performing millions of tests per year. Our products will revolutionize the genetic testing market by giving physicians, clinicians, nurse practitioners, other healthcare providers and ultimately consumers a greater ability to diagnose disease and measure heath status. With Akonni’s platform, we help them identify a broader set of diseases than today’s real-time PCR, microarray or immunoassay approaches, more quickly, accurately and at a lower overall cost. Our gel-drop platform and test readers also have applications in other genetic testing markets, such as for food security, agricultural, environmental testing and bio-terrorism. We also provide on-demand and fully automated ultra-rapid nucleic acid extraction products used to isolate nucleic acids from nearly any biological sample.